^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MSH6 expression

    i
    Entrez ID:
    2956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    Associations
    News

    Trials

    Apply
    A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) (NCT03835819)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    11/08/2024
    Initiation :
    01/02/2020
    Primary completion :
    06/04/2024
    Completion :
    05/01/2027
    FOLR1 • MLH1 • MSH6 • MSH2
    |
    MSH6 expression
    |
    Keytruda (pembrolizumab) • Elahere (mirvetuximab soravtansine-gynx)
    Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer (NCT02912572)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    04/19/2024
    Initiation :
    11/14/2016
    Primary completion :
    03/01/2025
    Completion :
    03/01/2027
    MSI • POLE • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR • POLE mutation • MSH6 expression
    |
    Bavencio (avelumab) • Talzenna (talazoparib) • Inlyta (axitinib)
    Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery (NCT03396926)
    Phase 2
    University of California, San Francisco
    Completed
    Last update posted :
    03/07/2024
    Initiation :
    04/18/2018
    Primary completion :
    01/30/2024
    Completion :
    01/30/2024
    MLH1 • MSH6 • MSH2
    |
    MSH6 expression
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • capecitabine
    Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (GARNET) (NCT02715284)
    Phase 1
    Tesaro, Inc.
    Recruiting
    Last update posted :
    08/22/2023
    Initiation :
    03/07/2016
    Primary completion :
    05/15/2026
    Completion :
    10/27/2027
    EGFR • ALK • MSI • MLH1 • MSH6 • MSH2
    |
    EGFR mutation • MSI-H/dMMR • ALK translocation • MSH6 expression
    |
    Jemperli (dostarlimab-gxly)
    Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients (NCT05846867)
    Phase 1/2
    Akeso
    Not yet recruiting
    Last update posted :
    05/08/2023
    Initiation :
    05/10/2023
    Primary completion :
    05/10/2024
    Completion :
    07/10/2025
    MLH1 • MSH6 • MSH2
    |
    PD-L1 expression • MSH6 expression
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Yidafan (ivonescimab) • drebuxelimab (AK119)
    Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study (NCT04500548)
    Phase 1
    National Cancer Institute (NCI)
    Withdrawn
    Last update posted :
    09/12/2022
    Initiation :
    01/28/2021
    Primary completion :
    06/21/2022
    Completion :
    06/21/2022
    TMB • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3
    |
    MSI-H/dMMR • MSH2 mutation • POLD1 mutation • PMS2 mutation • EPCAM expression • POLE mutation + POLD1 mutation • MSH6 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO) (NCT03186326)
    Phase 2
    Federation Francophone de Cancerologie Digestive
    Active, not recruiting
    Last update posted :
    08/19/2022
    Initiation :
    04/24/2018
    Primary completion :
    05/31/2022
    Completion :
    05/31/2023
    BRAF • MSI • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR • BRAF mutation • RAS mutation • MSH6 expression
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • Bavencio (avelumab) • oxaliplatin • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)